Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.
Fatma AboulnasrAshton KrogmanRondell P GrahamNathan W CumminsAnisha MisraEnrique M Garcia-RiveraJeff R AndersonSekar NatesampillaiLeonardo ClementeMurali AravamudanZilin NieThomas D Y ChungRichard BuickAndrew L FeldmanRebecca L KingAnne J NovakStephen M AnsellSaad KenderianAndrew D BadleyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells.See related commentary by de Miguel and Pardo, p. 5546.